Suchergebnisse - "Myeloma"

PubPharm (39.826)

51

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma : A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

52

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma : A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)

enthalten in: ClinicalTrials.gov | 2024

53

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy : Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

enthalten in: ClinicalTrials.gov | 2024

54

National Cancer Institute "Cancer Moonshot Biobank" : Cancer Moonshot Biobank Research Protocol

enthalten in: ClinicalTrials.gov | 2024

55

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma : A Phase Ib, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

56

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan : Empliciti® (Elotuzumab) Post-Marketing Surveillance Study for Patients With Multiple Myeloma in Taiwan

enthalten in: ClinicalTrials.gov | 2024

57

Evaluating the HYDRASHIFT 2/4 Daratumumab assay : a powerful approach to assess treatment response in multiple myeloma

enthalten in: Clinical chemistry and laboratory medicine | 2024

von Lee, H. | Kim, S. | Park, H.

58

Solitary Bone Plasmacytoma of the Skull Base With an Unusual Presentation

enthalten in: Ear, nose, & throat journal | 2024

von Huang, T. | Lin, C. | Chen, H.

59

Exploring natural killer cell-related biomarkers in multiple myeloma : a novel nature killer cell-related model predicting prognosis and immunotherapy response using single-cell study

enthalten in: Clinical and experimental medicine | 2024

von Zhao, J. | Wang, X. | Zhu, H. | +4

60

A Prognostic Survival Model Incorporating Patient-Reported Outcomes for Transplant-Ineligible Patients With Multiple Myeloma

enthalten in: The oncologist | 2024

von Mian, H. | Seow, H. | Balitsky, A. | +8